While the takeover war between Valeant Pharmaceuticals and Allergan is necessarily devoted to swaying investor sentiment, there is another key constituency to consider – physicians. After all, doctors represent another type of battleground for drug makers, since their prescribing decisions so readily affect pharmaceutical fortunes. So how might these treasured holders of prescribing pads react if Valeant succeeds in buying Allergan?. As it turns out, a sizeable portion of them have a dour view of the deal. A survey of 100 dermatologists and plastic surgeons – those who use Botox, line fillers and breast implants – finds that 44% will consider shifting business away from the company if the merger and cost-cuts go through.